types of MNC molecules. Individual patients can react against multiple antigens. It is the cellular arm of the immune response that is predominantly involved in immune reactivities, and a key question is whether we can use this information to generate antitumor T cells by immunizing patients using a vaccine.

In a pilot trial, we demonstrated that a modified peptide could consistently immunize cancer patients and generate T cells in their circulation that can recognize the cancer. Work by us and others has opened new possibilities for the development of effective immunotherapies for the treatment of cancer.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement